**Supplemental Table 1. Top 10 Antibiotic Agents by Expenditures by Year and Overall, 2010-2015.** (expenditures are presented in millions)

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Antibiotic | 2010  $\* (%) | 2011  $\* (%) | 2012  $\* (%) | 2013  $\* (%) | 2014  $\* (%) | 2015  $\* (%) | Total Expenditures  $\* (%) | P value\*\* |
| **Overall** |  |  |  |  |  |  |  |  |
| Doxycycline | 0.82 (7.8) | 0.80  (8.1) | 0.86  (10.2) | 1.9 (20.8) | 1.4 (15.7) | 1.2 (13.1) | |  | | --- | | 7.0 (12.5) | | | 0.1733 |
| Daptomycin | 0.50  (4.7) | 0.59  (6.0) | 0.61  (7.2) | 0.63  (6.9) | 1.3 (14.2) | 1.3 (14.7) | |  | | --- | | 4.9 (8.8) | | | 0.0111 |
| Linezolid | 0.69  (6.6) | 0.73  (7.5) | 0.71  (8.5) | 0.73  (8.0) | 0.74 (8.1) | 0.76 (8.6) | |  | | --- | | 4.4 (7.8) | | | 0.0483 |
| Minocycline | 0.80  (7.6) | 0.90  (9.2) | 0.67 (8.0) | 0.53  (5.8) | 0.42  (4.6) | 0.32 (3.7) | |  | | --- | | 3.6 (6.5) | | | 0.0171 |
| Piperacillin/ tazobactam | 0.75 (7.1) | 0.53  (5.4) | 0.46  (5.4) | 0.44  (4.8) | 0.46 (5.1) | 0.51 (5.8) | |  | | --- | | 3.2 (5.6) | | 0.2799 |
| Levofloxacin | 1.7 (15.9) | 0.97  (10.0) | 0.12  (1.4) | 0.12  (1.4) | 0.10  (1.2) | 0.09 (1.0) | |  | | --- | | 3.1 (5.5) | | | 0.0310 |
| Vancomycin | 0.49  (4.6) | 0.52  (5.3) | 0.52  (6.2) | 0.39  (4.2) | 0.33  (3.6) | 0.38 (4.4) | |  | | --- | | 2.6 (4.7) | | | 0.3420 |
| Azithromycin | 0.53  (5.0) | 0.49  (5.0) | 0.39  (4.6) | 0.35 (3.8) | 0.36 (3.9) | 0.36 (4.1) | |  | | --- | | 2.5 (4.4) | | | 0.0318 |
| Amoxicillin/ clavulanic acid | 0.49  (4.6) | 0.45 (4.6) | 0.36  (4.3) | 0.34  (3.7) | 0.47 (5.2) | 0.29 (3.3) | |  | | --- | | 2.4 (4.3) | | 0.4153 |
| Tobramycin | 0.28  (2.7) | 0.31  (3.1) | 0.35 (4.1) | 0.41 (4.5) | 0.35 (3.9) | 0.29 (3.2) | |  | | --- | | 2.0 (3.5) | | | 0.4174 |

\*Results are reported in $1,000,000s

\*\*P value is evaluating the trend in the proportion of expenditures over five years